Monitoring Agency Report

CSD/BM/SE/2026-27 Date: November 6, 2026 To To Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 530239 Scrip Symbol: SUVEN Dear Sir/Madam, Sub: Monitoring Agency Report for the quarter ended September 30, 2026 Pursuant to Regulation 162A of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018 and Regulation 32 (6) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Monitoring Agency (MA) Report issued by CRISIL Ratings Limited for the quarter ended September 30, 2026, regarding utilization of proceeds of the Preferential Issue of the Company. This is for your information and records. Thanking you. Yours faithfully, For Suven Life Sciences Limited K. Sangeetha Laxmi Company Secretary and Compliance officer Encl: as above Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com Monitoring Agency Report for Suven Life Sciences Limited for the quarter ended September 30, 2026 CRL/MAR/ARIL/2026-27/2030 November 06, 2026 Suven Life Sciences Limited 8-2-334, SDE Serene Chambers Road, Road No. 5, Avenue 7, Banjara Hills, Hyderabad–500034 Dear Sir, Monitoring Agency Report for the quarter ended September 30, 2026 - in relation to the Preferential Issue of Suven Life Sciences Limited (“the Company”) Pursuant to Regulation 162A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated May 15, 2025, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of Preferential Issue for the quarter ended September 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Report of the Monitoring Agency (MA) Name of the issuer: Suven Life Sciences Limited For quarter ended: September 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: Yes, however it is approved by shareholders vide resolution dated 25th August 2026 – Refer below Note Note - It relates to the reallocation of funds amongst the existing objects itself. The revised Net Proceeds structure post reallocation has been approved by the shareholders at the Annual General Meeting held on 25th August 2026. For more details Refer Note 1 on page 6. (b) Range of Deviation: Up to 10% Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) 1) Issuer Details: Name of the issuer: Suven Life Sciences Limited Names of the promoter: a. Venkateswarlu Jasti b. Sudharani Jasti Industry/sector to which it belongs: Pharmaceuticals 2) Issue Details Issue Period: June 21, 2025 to June 30, 2025 Type of issue (public/rights): Preferential Issue Type of specified securities: Convertible Warrants Grading, if any: NA Issue size: Rs 85,764.02 lakhs* Preferential Issue size comprises of convertible warrants of Rs 85,764.02 lakhs. (Refer Note1) *Crisil Ratings shall be monitoring the issue proceeds amount. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ Comments certifications considered Comments of the of the Particulars Reply by Monitoring Agency Monitoring Agency Board of for preparation of report Directors Management During the reported undertaking, Statutory quarter, the utilization Auditor Certificate^, towards the revised Notice to shareholders Whether all utilization is as per cost of objects is as per dated May 14th, 2025, No the disclosures in the Offer No the shareholder’s Corrigendum to notice Comments Document? approval dated 25th dated 28th May 2025, August 2026, for Special resolution dated change and variation in 25th August 2026, Bank the cost of objects. Statements Whether shareholder approval Management has been obtained in case of undertaking, No material deviations# from Yes Refer Note 1 on page 6 Statutory Auditor Comments expenditures disclosed in the Certificate^ Offer Document? Source of information/ Comments certifications considered Comments of the of the Particulars Reply by Monitoring Agency Monitoring Agency Board of for preparation of report Directors Whether the means of finance for the disclosed objects of the issue NA No Comments Comments has changed? Is there any major deviation# observed over the earlier NA No Comments Comments monitoring agency reports? Whether all Government /statutory approvals related to NA No Comments Comments the object(s) have been obtained? Whether all arrangements Management pertaining to technical undertaking, No NA No Comments assistance/collaboration are in Statutory Auditor Comments operation? Certificate^ Are there any favorable events improving the viability of these No No Comments Comments object(s)? Are there any unfavorable events affecting the viability of the No No Comments Comments object(s)? Is there any other relevant information that may materially No No No Comments affect the decision making of the Comments investors? #Where material deviation may be defined to mean: (a) Deviation in the objects or purposes for which the funds have been raised (b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents. NA represents Not Applicable ^On the basis of Certificate dated October 28, 2026, issued by M/s Karvy & C [Showing first 8,000 characters — download PDF for full document]